Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

Mostrar otras versiones (1)
Detalles Bibliográficos
Autores principales: Hopcroft, Lorna, Wigmore, Eleanor M., Williamson, Stuart C., Ros, Susana, Eberlein, Cath, Moss, Jennifer I., Urosevic, Jelena, Carnevalli, Larissa S., Talbot, Sara, Bradshaw, Lauren, Blaker, Catherine, Gunda, Sreeharsha, Owenson, Venetia, Hoffmann, Scott, Sutton, Daniel, Jones, Stewart, Goodwin, Richard J. A., Willis, Brandon S., Rooney, Claire, de Bruin, Elza C., Barry, Simon T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Author Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509253/
https://www.ncbi.nlm.nih.gov/pubmed/37726304
http://dx.doi.org/10.1038/s41523-023-00581-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509253/
https://www.ncbi.nlm.nih.gov/pubmed/37726304
http://dx.doi.org/10.1038/s41523-023-00581-8

Ejemplares similares